BCLI News and Press, Brainstorm Cell Therapeutics Inc. From 03/24/21

BrainStorm Cell Therapeutics (BCLI) soars 20% premarket after announcing topline data from Phase 2 trial evaluating three repeated administrations of NurOwn (MSC-NTF cells), each given 2 months apart, as a treatment for progressive multiple sclerosis ((MS)).The study achieved the pr...

Hall of Fame Resort & Entertainment Company (HOFV) +71% after NFT deal.Dolphin Entertainment (DLPN) +66% after NFT deal.Alithya Group (ALYA) +52% on acquisition of R3D ConseilColor Star Technology (CSCW) +41%.Aptose Biosciences (APTO) +39% on Q4 results.Cinedigm C...

BrainStorm Announces Positive Topline Data in Phase 2 Study Evaluating NurOwn® as a Treatment for Progressive MS NurOwn® was shown to be safe and well tolerated Clinically meaningful improvements observed in MS functional endpoints PR Newswire NEW YOR...

The FDA yesterday took the unusual step of issuing an update with further details on last month's feedback that a high-level data summary of BrainStorm Cell Therapeutics' (BCLI) NurOwn program for ALS did not provide substantial evidence to support a BLA application.The agency said it was iss...

BrainStorm to Present at SVB Leerink 10th Global Healthcare Conference PR Newswire NEW YORK , Feb. 23, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announce...

Gainers: ReTo Eco-Solutions (RETO) +93%.Celsion (CLSN) +62%.Rodgers Silicon Valley Acquisition (RSVA) +49%.Taoping (TAOP) +44%.RealNetworks (RNWK) +32%.Cooper Tire & Rubber (CTB) +30%.MICT (MICT) +26%.Conformis (CFMS) +26%.ATIF Holdings (ATIF) +25%.Vuzix (VUZI) +23%.Losers:...

Gainers: Celsion (CLSN) +54%, SunLink Health Systems (SSY) +27%, Citius Pharmaceuticals (CTXR) +26%, Can-Fite BioPharma (CANF) +19%, Aesthetic Medical International Holdings Group (AIH) +18%.Losers: Otonomy (OTIC) -43%, Brainstorm Cell Th...

BrainStorm Cell Therapeutics (BCLI) slumps 25% premarket after receiving FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase 3 clinical trial.The FDA has concluded that the current level of clinical data does not provide the threshold of su...

Otonomy (OTIC) -51% after Otividex fails late-stage Ménière’s disease study.Ebix (EBIX) -32% as auditor resigns after flagging material weakness.Energous (WATT) -20%.MoneyGram International (MGI) -17% on Q4 earnings.Petroleo Brasileiro S.A. - Petrobra...

BrainStorm Announces High-Level FDA Feedback on NurOwn® ALS Clinical Development Program FDA recommended generating additional clinical data to meet FDA's BLA requirements PR Newswire NEW YORK , Feb. 22, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics ...